Incannex Healthcare Inc. logo

Incannex Healthcare Inc.(IXHL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.97
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IXHL

11/13/2026: IXHL (1-star) is currently NOT-A-BUY. Pass it for now.

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing proprietary cannabinoid and psychedelic combination therapies. The company's primary strength lies in its diverse drug pipeline, highlighted by FDA Fast Track designation for its lead obstructive sleep apnea candidate, IHL-42X. Its primary investment story centers on high-reward clinical trial readouts and potential commercialization in large therapeutic markets. Key risks include a pre-revenue financial profile, ongoing cash burn, and the inherent uncertainty of clinical drug development. The stock suits risk-tolerant growth investors willing to monitor upcoming clinical milestones and regulatory progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-growth pipeline potential if clinical trials succeed, but lacks traditional revenue growth.
Momentum investorStrong fit while signal remains positiveMomentum participation is conditional on positive clinical trial catalysts and upward stock price breakouts.
Value investorWeak fitThe stock lacks fundamental value metrics, earnings, or cash generation to suit traditional value strategies.
Dividend investorWeak fitIncannex is a pre-revenue clinical-stage biopharma company that pays no dividends.
Low-risk investorWeak fitHigh clinical, regulatory, and price volatility risks make it unsuitable for risk-averse investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap clinical-stage biopharma stocks experience sharp price fluctuations based on news and market sentiment.
Valuation riskHighValuation is entirely speculative based on clinical potential rather than trailing financial earnings.
Competition risk (biopharmaceutical and clinical drug development)Medium / highWell-funded competitors may develop superior or faster-to-market alternative therapies.
Business qualityMediumThe business model relies on scientific and regulatory breakthroughs rather than established commercial franchises.
Dividend incomeLow / noneNo dividends are paid or anticipated as all capital is consumed by research operations.
Execution riskHighThe company's viability depends heavily on executing complex clinical trials and securing regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 24.72M USD
Price to earnings Ratio -
1Y Target Price 18.17
Price to earnings Ratio -
1Y Target Price 18.17
Volume (30-day avg) 76.3K shares
Beta 2.84
52 Weeks Range 1.91 - 14.91
Updated Date 11/15/2026
52 Weeks Range 1.91 - 14.91
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.25

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -18.1%
Avg. Invested days 14
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IXHL receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
IXHL has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2026 versus FY2025, strong earnings growth (+58.8%) is partially offset by soft cash generation (FCF margin 0.0%), negative revenue growth (-100.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
IXHL's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is IXHL's strongest growth driver at +58.8% FY2026 versus FY2025 (strong, 5 stars). By comparison, while revenue growth (-100.0%, negative) and free-cash-flow growth (-2.8%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 4.0% (soft) and 83.8% of outstanding shares are publicly tradable (strong). Insider ownership of 9.12% supports management-shareholder alignment.

Top 5 Institutional Investors

LPL Financial Corp 1.18%
Millennium Management LLC 0.76%
Jane Street Group LLC 0.62%
AdvisorShares Investments, LLC 0.49%
Susquehanna International Group, LLP 0.23%

Unit Economics (Per $1K Revenue)

★★★★★
IXHL generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 19.44%

Quantitative Style Profile

★★★★★
IXHL has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Commercial Product SalesLegacy or minor retail product sales where applicable, currently generating negligible or zero revenue.The company does not currently rely on commercial sales for income and operates as a pre-revenue developer.
Future Licensing & TherapeuticsAnticipated future commercialization, milestone payments, or out-licensing royalties from pipeline drugs like IHL-42X.Future financial returns depend entirely on successfully commercializing or licensing out its pipeline drug assets.

Valuation

Trailing PE -
Forward PE 3.78
Enterprise Value -43.47M
Price to Sales(TTM) 84.2
Enterprise Value -43.47M
Price to Sales(TTM) 84.2
Enterprise Value to Revenue 388.53
Enterprise Value to EBITDA -5.13
Shares Outstanding 12.55M
Shares Floating 10.51M
Shares Outstanding 12.55M
Shares Floating 10.51M
Percent Insiders 9.12
Percent Institutions 4

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.